BAFF CAR-T cells for hard-to-treat blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (LMY-922) that targets BAFF in people with certain blood cancers that have not responded to standard treatments. The goal is to see if it can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma, CLL, hairy cell leukemia, or multiple myeloma that has come back or not responded to at least 2 prior treatments (or 1 for hairy cell leukemia, or 3 for multiple myeloma).
- You have active disease that can be seen on scans or blood tests.
- Your kidneys, heart, lungs, and liver are working well enough (based on recent tests).
- You are not pregnant, breastfeeding, or have certain active infections (like HIV, hepatitis B/C, or uncontrolled infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called BAFF CAR-T cells (LMY-920) for people with certain types of lymphoma or multiple myeloma that have come back or not responded to previous treatments. The therapy uses your own immune cells, modified to attack cancer cells, and may offer a new option when standard treatments have not worked.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
This trial tests a new type of immune cell therapy (BAFF CAR-T cells) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded after at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if these engineered cells can fight the cancer.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.